Cart
sales@molnova.com
GSK-461364
CAS No. 929095-18-1
GSK-461364 ( GSK-461364A )
Catalog No. M16654 CAS No. 929095-18-1
A potent, selective, and reversible ATP-competitive PLK1 inhibitor with Ki of 2.2 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 113 | In Stock |
|
| 25MG | 195 | In Stock |
|
| 50MG | 354 | In Stock |
|
| 100MG | 528 | In Stock |
|
| 200MG | 755 | In Stock |
|
| 500MG | 1152 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-461364
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, and reversible ATP-competitive PLK1 inhibitor with Ki of 2.2 nM.
-
DescriptionA potent, selective, and reversible ATP-competitive PLK1 inhibitor with Ki of 2.2 nM; >390-fold greater selectivity for Plk1 than for Plk2 and Plk3 and 1,000-fold greater selectivity than for a panel of 48 other kinases; shows antiproliferative activity against >120 tumor cell lines and potently inhibits the proliferation with IC50s of <100 nM; shows clear antitumor activity in human tumor xenograft models.Blood Cancer Phase 1 Clinical
-
SynonymsGSK-461364A
-
PathwayCell Cycle/DNA Damage
-
TargetPLK
-
RecptorPLK1
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number929095-18-1
-
Formula Weight543.60
-
Molecular FormulaC27H28F3N5O2S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(N3C=NC4=CC=C(CN5CCN(C)CC5)C=C34)S1)N
-
Chemical Name2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Olmos D, et al. Clin Cancer Res. 2011 May 15;17(10):3420-30.
2. Gilmartin AG, et al. Cancer Res. 2009 Sep 1;69(17):6969-77.
3. Degenhardt Y, et al. Mol Cancer Ther. 2010 Jul;9(7):2079-89.
2. Gilmartin AG, et al. Cancer Res. 2009 Sep 1;69(17):6969-77.
3. Degenhardt Y, et al. Mol Cancer Ther. 2010 Jul;9(7):2079-89.
molnova catalog
related products
-
Rigosertib
Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM.
-
GSK-461364
A potent, selective, and reversible ATP-competitive PLK1 inhibitor with Ki of 2.2 nM.
-
5-ETHYL-4,5,6,7-TETR...
5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE targets PLK1.
